Skip to Main Content
Contribute Try STAT+ Today

Oxfam America has filed a complaint with securities regulators accusing Moderna (MRNA) of providing “misleading statements” and concealing material information about its dispute with the U.S. government over Covid-19 vaccine patents.

Specifically, the advocacy group maintained the company wrongfully described a simmering patent dispute with the National Institutes of Health in its regulatory filings over the past year as theoretical when, in fact, the federal government was threatening litigation. Oxfam contended Moderna should have expressly acknowledged this risk, and that its failure to do so violated securities laws.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment